ArticleFrontiers in endocrinology2025
Salivary free aldosterone awakening response and cardiovascular risk in men with CHD, hypertension, and healthy controls.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mineralocorticoid hormone aldosterone plays a key role in blood pressure regulation and the development of cardiovascular disease. However, the biological mechanisms that underly prospective associations with negative health outcomes are not fully understood. We compared the awakening response of biologically active salivary aldosterone (AldAR) between male participants with coronary heart disease (CHD), essential hypertension (EHT), and normotension (NT) and additionally examined prospective associations with biological CHD risk factors. Methods: At baseline, 60 CHD patients, 40 EHT and 44 NT repeatedly assessed the AldAR over two consecutive days. In 97 participants, prospective CHD risk was assessed by changes from baseline to follow-up 2.95 ± 0.07 ( Results: Whereas NT showed the regular AldAR, EHT had higher overall aldosterone levels ( Conclusions: We found evidence for altered AldAR in CHD and EHT with higher AldAR predicting higher CHD risk, particularly in relation to systemic inflammation and dyslipidemia. Elevated AldAR levels may contribute to the pathogenesis of atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.